Atara Biotherapeutics to Host EBV and MS Day
- Scientific Experts Join Atara Management Team to Discuss Role of EBV in MS and Clinical Development of ATA188
- Live Conference Call and Webcast on March 22 at 4:00 p.m. EDT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 – 6:00 p.m. EDT.
Dr. Pascal Touchon, President and Chief Executive Officer along with other members of the Atara management team, will present a comprehensive overview of several topics including: EBV as the cause of MS; history and development of ATA188; review of Phase 1 clinical and biomarker data; and an overview of upcoming key catalysts.
The Atara management team will be joined by the following renowned scientific experts, who will also share their perspectives:
- Mark Freedman, HBSc, MSc, MD, CSPQ FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa and Director of MS Research, Ottawa Hospital Research Institute, Ottawa, Canada
- Rajiv Khanna, BSc, MSc, PhD, Director of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Australia
- Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics and Genetics, Stanford University, Stanford, California
Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13727293. A live webcast with accompanying slides can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 60 days following the live webcast.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315006164/en/
Source: Atara Biotherapeutics, Inc.
View this news release online at: